Implantable Cardioverter Defibrillator Therapy in Patients with Cardiac Sarcoidosis
Implantable Cardioverter Defibrillator Therapy in Patients with Cardiac Sarcoidosis
复制标题
DOI：
10.1111/j.1540-8167.2012.02350.x
复制
发表时间：
2012-09-01
影响因子：
2.7
通讯作者：
Sauer, William H.
中科院分区：
文献类型：
--
作者：
Schuller, Joseph L.;Zipse, Matthew;Sauer, William H.
心脏结节病中的ICD电击。背景资料：植入式心律转复除颤器（ICD）适用于部分心脏结节病（CS）患者，以预防猝死。然而，关于这些患者中ICD治疗的事件发生率的数据很少。我们试图确定ICD治疗在该患者人群中的发生率和特征。方法：我们对3家机构植入ICD的患者进行了队列研究。病例为CS患者，植入ICD用于猝死的一级或二级预防。此外，我们纳入了与临床试验中报告的ICD治疗率的历史对照比较，评价ICD对猝死的一级和二级预防。结果如下：在确定的112例CS受试者中，36例（32.1%）在平均29.2个月的随访期内接受了室性快速性心律失常（VT）的适当治疗。16例（14.2%）CS受试者发生VT风暴（24小时内>3次发作）。13例CS受试者（11.6%）发生治疗不当。与适当ICD治疗相关的协变量包括左心室射血分数（LVEF）
ICD Shocks in Cardiac Sarcoidosis. Background: An implantable cardioverter defibrillator (ICD) is indicated for some patients with cardiac sarcoidosis (CS) for prevention of sudden death. However, there are little data regarding the event rates of ICD therapies in these patients. We sought to identify the incidence and characteristics of ICD therapies in this patient population. Methods: We performed a cohort study of patients with ICDs at 3 institutions. Cases were those patients with CS and an ICD implanted for primary or secondary prevention of sudden death. Additionally, we included a comparison with historical controls of ICD therapy rates reported in clinical trials evaluating the ICD for primary and secondary prevention of sudden death. Results: Of the 112 CS subjects identified, 36 (32.1%) received appropriate therapies for ventricular tachyarrhythmias (VT) over a mean follow-up period of 29.2 months. VT storm (>3 episodes in 24 hours) occurred in 16 (14.2%) CS subjects. Inappropriate therapies occurred in 13 CS subjects (11.6%). Covariates associated with appropriate ICD therapies included left ventricular ejection fraction (LVEF)